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Summary
We propose a general novel class of joint models to analyze recurrent events that has a wide
variety of applications. The application of focus on this paper is to model the bleeding and
transfusion events in Myelodyplastic Syndrome (MDS) studies, where patients may die or
withdraw from the study early due to adverse events or other reasons, such as consent withdrawal
or required alternative therapy during the study. The proposed model accommodates multiple
recurrent events and multivariate informative censoring through a shared random effects model.
The random effects model captures both within-subject and within-event dependence
simultaneously. We construct the likelihood function for the semi-parametric joint model and
develop an EM algorithm for inference. The computational burden does not increase with the
number of types of recurrent events. We utilize the MDS clinical trial data to illustrate our
proposed methodology. We also conduct a number of simulations to examine the performance of
the proposed model.
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1 Introduction
In many biomedical studies, patients may experience the same type of recurrent event
repeatedly over time, such as bleeding, multiple infections and relapse. In such studies, the
patients may also be subject to informative censoring, which can be death or administrative
withdrawal due to adverse events. In our motivating case study of MDS, the interest lies in
evaluating a treatment effect of an investigational product (IP) for reducing recurrent
bleeding or transfusion events among lower risk MDS patients receiving disease modifying
therapy. In addition, we also consider early subject discontinuation due to disease
progression to acute myeloid leukemia (AML), death, adverse events, switching to
alternative therapies, or other reasons.
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A major motivation for our proposed methodology is that we have multivariate types of
recurrent events as well as multivariate informative censoring. Since the censoring times are
associated with the recurrent events, existing methods on recurrent events (e.g., Andersen
and Gill, 1982; Prentice, Williams and Peterson, 1981; and Wei, Lin and Weissfeld, 1989)
that are valid under noninformative censoring, may yield misleading results if applied in our
setting, for example. Therefore, valid procedures which jointly take the recurrent events and
informative censoring times into account in the analysis need to be developed. Marginal
models have been proposed to analyze recurrent event data in the presence of a single
terminal event (a univariate informative censoring time); see Cook and Lawless (1997),
Ghosh and Lin (2000; 2002), and Chen and Cook (2004). To capture the recurrence given an
individual’s past event history, a more attractive approach is to adopt a joint modeling
approach for both recurrent events and informative censoring times. Approaches along these
lines include the shared frailty model by Wang, Qin and Chiang (2001), Huang and Wang
(2004), Liu, Wolfe and Huang (2004), and Liu and Huang (2008), which model the
recurrent event and informative censoring time separately but allow a common frailty shared
by these two models. More general classes of transformation models and their theoretical
properties have been more recently considered by Zeng and Lin (2009) and Zhu et al.
(2011).
Recently, Zhu et al. (2010) generalize the above approaches to model multivariate recurrent
events and one terminal event but their method relies on a very special frailty structure in
recurrent events. Later, Zhu et al. (2011) consider a more general frailty structure and the
frailties from each type of recurrent event are included into the model for the terminal event;
the nonparametric maximum likelihood approach is used for inference. However, one
challenging problem in implementing this approach is that one has to deal with high-
dimensional numerical integrations whose dimensions increase with the number of recurrent
events. This problem will become even more burdensome if dependent censoring time is
also present in addition to the terminal event, as seen in our MDS application. Thus, in this
paper, we present a joint model for handling multiple recurrent events and multiple
informative censoring times. Specifically, we allow an event-specific frailty to account for
the within-subject-within-event dependence while adopting another common frailty to be
shared by all recurrent events and informative censoring times. Using this structure, our
inference for the model parameters avoids high-dimensional numerical integration, which
can be inaccurate when the number of event types is moderate to large. We propose a semi-
parametric model, use a nonparametric maximum likelihood estimation (NPMLE) approach
for inference, and develop a simple EM-algorithm for estimation of the NPMLE’s.
The rest of the paper is organized as follows. In Section 2, we propose the joint models for
multiple recurrent events in the presence of multiple types of informative censoring, discuss
the inference procedure, and examine the asymptotic properties. In Section 3, we carry out
an extensive simulation study to examine the empirical performance of the proposed joint
model and inference procedure. In Section 4, we present a detailed analysis of a real dataset
from a phase 2, randomized, double blind, placebo controlled MDS clinical trial. We
conclude the paper with a brief discussion in Section 5.
2 Proposed Methodology
2.1 Joint models
We use joint models to analyze multiple recurrent events subject to multiple types of
informative censoring. In these joint models, the subject-specific random effects will be
used to represent the latent dependence between the recurrent events and the informative
censoring times. Specifically, for recurrent events of type l, l = 1, …, L, we propose the
following intensity model:
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where Ail(t) is the intensity function for subject i, Xi(t) denotes external covariates associated
with subject i, Zi(t) includes a constant term and is part of Xi(t), Wi(t) includes constant term
and part of Xi(t), Al(t) is an unknown baseline cumulative intensity function, bil is a subject
and event-specific random effect, and ξi is a subject random effect shared by all the events.
Additionally, we assume that for each l, the bil, l = 1, …, L are iid N(0, Σl) and the ξi’s are
iid N(0, Ψ) and independent of the bil’s. For an informative censoring time of type k, k = 1,
…, K, we propose the following proportional hazards model:
where λik(t) = dΛik(t)/dt is the hazard function for the type k informative censoring time for
subject i, λk(t) is an unknown baseline hazard function and both γk and ϕk are unknown
parameters. Here, ϕk ◦ Z̃i(t) denotes the component-wise product. Thus, the proposed joint
model can simultaneously estimate the covariate effects on the recurrent events and
informative censoring times. The random effect ξi captures the latent dependence between
recurrent events and survival times, where the dependence is reflected in the parameter ϕk.
Specifically, if the variance of ξi is zero, then the dependence among the recurrent events is
completely due to the covariates; if ϕk = 0, then the dependence between the recurrent
events and the survival event k is captured by the covariates, while ϕk > 0 or ϕk < 0 reflects
the possible positive correlation or negative correlation respectively, due to some
unobserved factors.
In our MDS application, we will specifically choose bil to be univariate, Xi(t) = X̃i(t), Wi(t) =
1, and Zi(t) = Z̃i(t) = 1. Moreover, in the MDS application, L denotes the number of types of
recurrent events (bleeding and transfusion), i.e., L = 2, and the terminal event is death or
AML, so K = 1. Thus, a 2 × 2 covariance matrix is assumed between the bleeding and
transfusion events and ξi is the common random effect shared by the bleeding and
transfusion events and the terminal event. In general, when L > 2, a compound symmetry
covariance structure is assumed between recurrent events. We may further assume β1 = … =
βL. Under these assumptions, the above model becomes
and
2.2 Observed-data likelihood
The observed data consists of the recurrent events and survival endpoints:
where Ci is the noninformative censoring time (for example, administrative censoring) and
Δik is an indicator variable I(Tik = Yi), that is, the observed endpoint is the kth survival event.
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For this data structure, and under our model assumptions, the observed-data likelihood
function is proportional to
where δNil(t) denotes the jumps of Nil at time t.
2.3 Inference procedure
The estimation and inference for all the parameters can be carried out by nonparametric
maximum likelihood estimation. The EM algorithm is used to compute the maximum
likelihood estimates treating bi as missing data. In the M-step of the EM algorithm, we
maximize the conditional expectation of the complete-data log-likelihood function given the
observed data and the current parameter values. Note that the complete-data log-likelihood
takes a similar form as the usual Cox partial log-likelihood function. Thus, the maximization
for the regression parameters is equivalent to maximizing some modified expression of the
Cox partial likelihood function while the estimation for the baseline cumulative hazard
function is a Breslow-type estimator. Specifically, we solve the following estimating
equations for updating the regression coefficients: for l = 1, …, L,
for k = 1, …, K,
The one-step Newton-Raphson iteration can be used to update the regression coefficients.
The baseline functions Al and Λk can be updated as
and
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where the superscript “new” means that the parameter values are the ones from solving the
previous equations. Finally, Σl can be updated as  and Ψ is given by
.
In all these expressions, Ê[·] denotes the conditional expectation of the missing data, i.e., bil
and ξi, given the observed data. Since this conditional density is proportional to
the conditional expectation is usually calculated using numerical integration algorithms such
as Gaussian Quadrature. An important point here is that although L can be large, the actual
expectation to be calculated in the M-step involves ξi and at most one of the bil’s. Therefore,
the dimension of the numerical integration is at most two in our MDS application.
We iterate between the E-step and M-step until convergence. To estimate the asymptotic
covariance matrix of the parameter estimates, one approach is to use the Louis formula
(Louis, 1982) to estimate the observed information matrix for all the parameters including
the β’s, γ’s, ϕi’s, Σ and all the jumps of Al and Λk. The asymptotic covariance matrix is then
the inverse of this matrix. Alternatively, when we are only interested in inference on the
regression parameters, another approach is to calculate the profile log-likelihood function
for these parameters in a neighborhood of their estimates and by profile likelihood theory,
the inverse of the negative curvature of this profile log-likelihood function is a consistent
estimator for the asymptotic covariance matrix for the parameters of interest. Specifically, to
calculate the profile log-likelihood function, we can simply apply the same EM algorithm as
before but hold the regression parameters fixed in the EM iterations.
2.4 Asymptotic properties
We provide the asymptotic properties for the NPMLE’s. We impose the following
conditions.
(C1) The true parameter value for θ ≡ (βl, Σl, l = 1, …, L, γk, ϕk, k = 1, …, K, Ψ),
denoted by θ0, belongs to the interior of a compact set in the domain. Additionally, Al
and Λk are continuously differentiable and bounded away from zero in [0, τ], where τ is
the study duration.
(C2) With probability one, Xi(·), Wi(·), X̃i(·) and Z̃i(·), Zi(·) are left-continuous with
uniformly bounded left- and right- derivatives in [0, τ].
(C3) With probability one, P(Ci ≥ τ|Zi) > δ0 > 0 for some constant δ0.
(C4) If there exist c(t) and υ such that c(t) + υTXi(t) = 0 with probability 1, then c(t) = 0
and υ = 0. The same condition holds for X ̃i(t). In addition, there exists some t ∈ [0, τ]
such that the linear space spanned by {w : w ∈ supp(Wi(t))} is the whole space of bil and
the linear space spanned by {z : z ∈ supp(Zi(t))} is the whole space of ξi. The latter also
holds for {Z̃i(t)} for some t.
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In our MDS application, Wi = Zi = Z ̃i = 1 and Xi(t) = X̃i(t) is time-independent. Then
conditions (C2) and (C4) hold when [1, Xi] are linearly independent with positive
probability. Under these conditions, it is easy to see that conditions (D1)–(D8) in Zeng and
Lin (2010) hold. Therefore, following their arguments of Section 10.1, we obtain the
following theorem.
Theorem 1. Under conditions (C1)–(C4), the NPMLE’s for θ, denoted by θ̂, and (Âl, Âk)
satisfy
where  is a mean-zero and tight Gaussian process in Rs × BV [0, τ]L+K with s = dim(θ0).
Moreover, the asymptotic covariance matrix of  attains the semi-parametric
efficiency bound.
Following Zeng and Lin (2010), we also obtain that the profile log-likelihood yields a
consistent estimator of the asymptotic covariance matrix of θ̂.
3 Simulation Study
We conducted a set of extensive simulation studies to examine the small-sample
performance of the proposed model. In the simulation studies, we let W = Z = 1. The
covariates in the model are time-independent and consist of X1 which is taken to have a
Bernoulli distribution, and X2 is taken to have a uniform distribution in [0, 1]. The baseline
functions for the recurrent events are set to be constants which may vary for different types
of events. We consider two types of survival events and the baseline hazard function for the
first event time is a constant while the baseline hazard function for the second event time is
linear in time. We choose different values for the β’s, γ’s and ϕ’s to reflect the different
covariate effects on the recurrent events or survival events as well as the association
between the recurrent events and survival events, where the actual values are given in Tables
1 and 2. In our simulation design, we take L = 2, K = 2 and L = 4, K = 2, and we consider
sample sizes of n = 400 and n = 800. For L = 2 and K = 2, the average numbers of the two
types of recurrent events per subject is 0.25 and 0.3, while the average censoring rate is
around 59% and 54%, respectively. For L = 4 and K = 2, the average numbers of recurrent
events are, respectively, 0.25, 0.39, 1.37 and 1.84, and the censoring rates are 37% and 64%.
For each simulated dataset, we applied the proposed methodology to estimate the
parameters. The EM algorithm converges for every simulated data. Since the number of
parameters to be estimated is large, we use the profile likelihood method to estimate the
asymptotic covariance matrix of the estimates of the regression coefficients. In the profile
likelihood method, the perturbation parameter in computing the second order numerical
differences of the log-likelihood function is set to be n−1/2. The results from 1,000 replicates
are summarized in Tables 1 and 2. In the tables, βlk denotes the coefficient of Xk in the lth
recurrent event and γqk is the coefficient of Xk in the qth survival event. The column “Est” is
the average value of the estimates from 1,000 replicates and the column “SD” is the standard
deviation of the estimates. The column “ESE” reports the average of the estimated standard
errors and the column “CP” is the coverage probability for 95% confidence intervals based
on asymptotic normality, where the coverage for the variance estimates uses the
Satterthwaite approximation in order to correct for the skewness in these parameter
estimates. For the estimates of the baseline functions, we also report the average mean
square errors in the tables.
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The results indicate that the proposed method works well in real settings with small bias,
yielding precise estimates of the variability and appropriate coverage probabilities. The
performance improves with increasing sample sizes. The prediction of the baseline
cumulative functions in both the recurrent events and survival events is accurate. The
estimation for ϕ’s, the parameters capturing the dependence due to latent effects among all
these endpoints, tends to have a wide confidence intervals. This phenomenon has been
observed in some previous work (Zeng and Lin, 2009). It may be because that ϕ’s are
equivalent to the scaled variance components of the frailties in survival endpoints so may
not have sufficiently large information to be estimated well.
We further consider a simulation study with a time by covariate interaction. The models are
similar to the first simulation study with L = 2 and K = 2 except that the baseline hazard
functions are both constants and in both the recurrent event model and the survival model,
the covariates are X and X * t where X is generated from a uniform [0, 1] distribution. In the
simulations, the average numbers of the two types of recurrent events are 0.25 and 0.33
while the censoring rates are 80% and 24% for the two types of survival endpoints. The
results from 1,000 replicates are given in Table 3. Similar conclusions as those of Tables 1
and 2 are obtained.
4 MDS Clinical Trial
The proposed method is applied to a phase 2, randomized, double blind, placebo controlled
clinical trial in which lower risk MDS patients were treated with MDS disease modifying
therapies. One of the major goals of the trial is to evaluate the IP (treatment) effect on
reduction of platelet transfusion and bleeding events under this setting. It is known that the
most common side effect of MDS disease modifying therapies is thrombocytopenia (platelet
count < 100 × 109/L). Low platelet counts will prevent the on-schedule of therapies
administered and increase the risk of bleeding, and thus result in higher morbidity. Platelet
transfusion interventions are often required therapeutically (given to patients who are
actively bleeding) and prophylactically (to prevent future bleeding). Therefore, the incidence
of platelet transfusion intervention and bleeding event occurrence are highly correlated.
Thus, the composite endpoint of bleeding events and platelet transfusion events is currently
being explored for future clinical program development. Informative censoring events are
also included in this analysis. These events, which include death or requirement of
alternative therapies, lead early study discontinuation and hence these termination events are
accounted for in the analysis model appropriately.
The trial was conducted in multiple centers in the United States from 2008 to 2009. A total
of 106 subjects were enrolled in the study, 38 (36%) subjects received placebo (standard of
care) and 68 (64%) subjects received one of the two dose cohorts of the investigational
product. Subjects were randomized and stratified by baseline platelet count 50 × 109/L. Two
subjects were excluded from the analysis due to not receiving any investigational product.
The median follow-up time was 133 days and during the follow-up, on average, patients
experienced 1.6 bleeding and 4.8 transfusion events. Furthermore, potential informative
censoring events were Acute Myeloid Leukemia (AML) or death (7 cases), or other
informative censoring reasons (35 cases) including administrative decision (14 cases),
adverse events (13 cases), and requirement for alternative therapy (8 cases). In addition to
the investigational product received (yes/no), the other covariates included in the analysis
include stratification factor (platelet count status at baseline) and the baseline disease risk
status of patients. The latter is classified into higher-risk (IPSS INT-1, INT-2 and high) and
lower-risk (IPSS low) groups based on a subject’s disease characteristics. Table 4 shows
some descriptive statistics for this trial, including platelet, risk, death rate, informative
censoring, transfusion, and bleeding information.
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Since the incidence of platelet transfusion intervention and bleeding event occurrence are
highly correlated, we first exclude those events which are apparently caused by each other
from the analysis. Specifically, any transfusion induced within one week of some bleeding
event is considered as the consequence of the bleeding and, therefore is excluded. In
addition, any transfusions within 7 days of each other are very likely to be due to
administrative purposes and are therefore also considered as a single platelet transfusion
event. Therefore, we believe that the remaining transfusion events are the patient’s self-
spontaneous events and are medical events not due to bleeding. In the data for our analysis,
the patients, on average, experienced 1.42 bleeding events and 1.77 transfusions.
We fit our proposed model to analyze the data with two types of recurrent events (L = 2).
Since there were only 7 AML or death cases, we combine both death and informative
dropout into a singe type of survival endpoint so K = 1. We start with the same initial values
as in the simulations, and the perturbation parameter that is chosen in the variance
estimation is , where n is the number of patients. The estimates, standard errors (SEs),
and p-values from the joint analysis based on the proposed method and the separate analysis
are given in Table 5. Table 5 shows that the treatment appears to reduce both the bleeding
incidences by 16% (1 − exp(−0.177)) or transfusions incidence by 51%. Moreover, there
appears to be marginal evidence that the treatment would result in fewer deaths or early
withdrawal. The patients with higher baseline platelet counts tend to experience less
bleeding or transfusions, and the patients in the higher-risk group are likely to experience
events and die or withdraw from the study. Although the estimate of ϕ does not really
indicate strong evidence for the association between the recurrent events and the survival
endpoint maybe due to small data size, the large variability of  and  reveals strong
dependence between the two types of recurrent events and a strong dependence between all
events in general. Even though ϕ is not significant at the 5% significance level, we still see
from Table 5 that there are some differences in the p-values between the proposed joint
analysis and the separate analysis. In particular, the treatment effects for bleeding events
from the joint analysis and the separate analysis have the opposite signs, although they both
are not significant, and the risk group is significantly associated with the survival endpoint
in the joint analysis while it is not if we analyze the survival endpoint separately. Figure 1
shows the estimated cumulative intensity function and cumulative hazard function. It shows
a steady constant risk for both bleeding events and transfusion events.
Since transfusion and bleeding events may be treated as the events concerning the same
status of patients clinically, we also conducted an analysis by combining these two recurrent
events into one composite endpoint. As before, we not only exclude any transfusions
induced within one week of some bleeding events, but also exclude any transfusions within
7 days of a previous transfusion. The results from this composite analysis are given in Table
5, which also indicates that the treatment, although not statistically significant, tends to
reduce the occurrence of bleeding/transfusion and the risk of death or withdrawal from the
study. The strong evidence for the association between the recurrent events and the survival
endpoint is still apparent.
5 Concluding Remarks
We have proposed a joint model for analyzing multiple types of recurrent events and
multiple types of informative censoring times. The joint model accounts for within-event
dependence and also between-event dependence through a decomposition of event-specific
frailty and the shared frailty. A major advantage of this proposed model is that it allows any
number of types of events without resorting to high-dimensional numerical integration due
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to the number of events in the inference. We have applied the proposed model to analyze an
MDS clinical trial.
Our joint models can be easily used for future prediction, for example, given one’s recurrent
event history, how likely he or she will experience one type of recurrent event or drop out
after time t. The confidence intervals of the prediction can be constructed using the Delta
method. Although the EM algorithm converges, it can be slow with a large number of
events. An alternative approach is to use a penalized quadrature approach in Liu and Huang
(2010). A substantial numerical comparison will be interesting.
Although we use the proportional intensity and proportional hazards model in the joint
model, other transformation models can be easily incorporated into the modeling
formulation. In addition, we can generalize our model to incorporate longitudinal
biomarkers into the analysis, for example, the platelet biomarker is measured over time in
the MDS study. Other complex features such as time-varying treatment effects can also be
included in this joint model.
The detailed development of the implementation of the proposed algorithm, and the SAS
code JointRT with an illustrative example including the SAS output and data sets are given
in the Web based supplementary materials. The MDS data is confidential and, thus, it is not
available for the public release.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Estimated baseline functions in the analysis of MDS data: (a) the solid curve is the estimated
cumulative intensity function for bleeding events and the dashed curve is the estimated
cumulative intensity function for transfusion events; (b) the solid curve is the estimated
cumulative hazards function for survival endpoint.
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Table 4
Descriptive Information of MDS Study
Control arm (n = 38) Treatment arm (n = 68)
High baseline platelet(%) 47.4% 50.0%
High risk (%) 84.2% 79.4%
Death/AML rate (%) 7.9% 5.9%
Informative censoring (%) 47.4% 25.0%
# Transfusion/patient 6.105 4.029
# Bleeding/patient 1.684 1.559
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